Related Experiment Videos
The significance of controls in Lyme arthritis of children
Insights
This study evaluated the specificity of Lyme disease (LD) diagnostic tests using control groups. Results indicate that these serologic tests are highly specific, with no significant antibody levels found in controls.
Area of Science:
- Medical research
- Immunology
- Rheumatology
Background:
- Lyme disease (LD) diagnosis can be challenging, particularly in pediatric rheumatology.
- Serologic tests for LD antibodies need clear specificity definitions.
- Establishing reliable clinical-laboratory correlations in Lyme arthritis is crucial.
Purpose of the Study:
- To define the specificity of Lyme disease seropositivity and seronegativity.
- To evaluate the utility of specific control groups for Lyme arthritis studies.
- To assess the accuracy of serologic tests for Borrelia burgdorferi (Bb) antibodies.
Main Methods:
- Development of three control groups: children with other rheumatic disorders, relatives of LD cases, and individuals with intense environmental exposure to LD.
- Sera testing using indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) for antibodies to Borrelia burgdorferi (Bb).
- Analysis of serologic results from 106 control individuals.
Main Results:
- Of 57 children with rheumatic disorders, only 4 (7%) showed borderline non-specific antibody levels (1:64 by IFA).
- All 7 household relatives and 42 intensely Bb-exposed individuals had non-reactive sera.
- None of the 106 control subjects reached a clinically significant antibody level.
Conclusions:
- The study demonstrates high specificity of serologic tests for Lyme disease.
- Selected control groups are valuable for clarifying ambiguities in Lyme arthritis diagnosis.
- These findings support the reliability of serologic testing in diagnosing Lyme disease.
Abstract:
In order to better define the specificity of Lyme disease (LD) seropositivity and seronegativity during a study of Lyme arthritis in a pediatric rheumatology population, three groups of controls are in the process of being developed. Children with other rheumatic disorders. Siblings and parents of children with Lyme arthritis. Individuals with intense environmental exposure to LD. Sera from each have been tested for antibody to Borrelia burgdorferi (Bb), by indirect immunofluorescence assay (IFA), enzyme linked immunosorbent assay (ELISA), or both. Of the 57 children with rheumatic disorders of whom 25 had JRA, 4 (7%) reached a border zone, non-specific level of 1:64 by IFA, and 53 sera were non-reactive. 7 household relatives of LD cases had non-reactive sera. The 42 intensely Bb-exposed individuals all had non-reactive sera. The fact that none of the 106 controls attained a clinically significant level of antibody is a general indication of the specificity of the serologic tests. The use of selected control groups such as these might potentially solve the ambiguities in clinical-laboratory correlations in Lyme arthritis.